Compare Stocks: MDNAF, KLRS, PCSC, and RANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRS Kalaris Therapeutics	$3.95 -3.0%	$4.30	$2.14 ▼ $11.88	$93.85M	0.2	153,544 shs	9,794 shs
MDNAF Medicenna Therapeutics	$0.27	$0.28	$0.23 ▼ $1.43	$24.83M	1.78	42,560 shs	24,019 shs
PCSC Perceptive Capital Solutions	$11.95	$11.41	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A
RANI Rani Therapeutics	$0.77 -3.2%	$0.78	$0.44 ▼ $3.87	$94.89M	0.78	1.02 million shs	169,807 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRS Kalaris Therapeutics	0.00%	+15.95%	-8.33%	-13.95%	+52.43%
MDNAF Medicenna Therapeutics	0.00%	+7.60%	+3.14%	-45.10%	+26,899,900.00%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+10.65%	+5.94%	-9.23%
RANI Rani Therapeutics	0.00%	+2.31%	+15.25%	-25.98%	+50.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KLRS Kalaris Therapeutics	$3.95 -3.0%	$4.30	$2.14 ▼ $11.88	$93.85M	0.2	153,544 shs	9,794 shs
MDNAF Medicenna Therapeutics	$0.27	$0.28	$0.23 ▼ $1.43	$24.83M	1.78	42,560 shs	24,019 shs
PCSC Perceptive Capital Solutions	$11.95	$11.41	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A
RANI Rani Therapeutics	$0.77 -3.2%	$0.78	$0.44 ▼ $3.87	$94.89M	0.78	1.02 million shs	169,807 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KLRS Kalaris Therapeutics	0.00%	+15.95%	-8.33%	-13.95%	+52.43%
MDNAF Medicenna Therapeutics	0.00%	+7.60%	+3.14%	-45.10%	+26,899,900.00%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+10.65%	+5.94%	-9.23%
RANI Rani Therapeutics	0.00%	+2.31%	+15.25%	-25.98%	+50.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KLRS Kalaris Therapeutics	2.88	Moderate Buy	$18.75	374.80% Upside
MDNAF Medicenna Therapeutics	2.00	Hold	N/A	N/A
PCSC Perceptive Capital Solutions	1.00	Sell	N/A	N/A
RANI Rani Therapeutics	2.60	Moderate Buy	$8.75	1,040.81% Upside

Current Analyst Ratings Breakdown

Latest MDNAF, KLRS, PCSC, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/17/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	KLRS Kalaris Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/9/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/20/2026	RANI Rani Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
5/14/2026	KLRS Kalaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$4.21 per share	N/A
MDNAF Medicenna Therapeutics	N/A	N/A	N/A	N/A	$0.02 per share	N/A
PCSC Perceptive Capital Solutions	N/A	N/A	$0.09 per share	127.23	($0.77) per share	N/A
RANI Rani Therapeutics	$1.63M	58.29	N/A	N/A	$0.34 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KLRS Kalaris Therapeutics	-$43.44M	-$2.15	N/A	N/A	N/A	N/A	-72.78%	-43.49%	N/A
MDNAF Medicenna Therapeutics	-$13.32M	-$0.16	N/A	N/A	N/A	N/A	-1.37%	-0.65%	N/A
PCSC Perceptive Capital Solutions	$840K	-$0.06	N/A	N/A	N/A	N/A	-2.70%	-0.84%	N/A
RANI Rani Therapeutics	-$29.67M	-$0.41	N/A	N/A	N/A	N/A	-206.46%	-83.95%	N/A

Latest MDNAF, KLRS, PCSC, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/15/2026	Q2 2026	PCSC Perceptive Capital Solutions	N/A	-$0.01	N/A	-$0.01	N/A	N/A
6/25/2026	Q4 2026	MDNAF Medicenna Therapeutics	-$0.05	-$0.05	N/A	-$0.06	N/A	N/A
5/15/2026	Q1 2026	RANI Rani Therapeutics	-$0.06	-$0.04	+$0.02	-$0.04	$1.13 million	$1.71 million
5/12/2026	Q1 2026	KLRS Kalaris Therapeutics	-$0.52	-$0.46	+$0.06	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
MDNAF Medicenna Therapeutics	N/A	N/A	N/A	N/A	N/A
PCSC Perceptive Capital Solutions	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KLRS Kalaris Therapeutics	N/A	12.19	12.19
MDNAF Medicenna Therapeutics	N/A	1.52	1.52
PCSC Perceptive Capital Solutions	N/A	0.20	0.20
RANI Rani Therapeutics	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KLRS Kalaris Therapeutics	66.05%
MDNAF Medicenna Therapeutics	35.85%
PCSC Perceptive Capital Solutions	N/A
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
KLRS Kalaris Therapeutics	68.10%
MDNAF Medicenna Therapeutics	33.10%
PCSC Perceptive Capital Solutions	22.06%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KLRS Kalaris Therapeutics	110	23.79 million	7.59 million	N/A
MDNAF Medicenna Therapeutics	20	92.30 million	61.75 million	N/A
PCSC Perceptive Capital Solutions	N/A	8.16 million	6.36 million	N/A
RANI Rani Therapeutics	110	123.88 million	90.77 million	Optionable

MDNAF, KLRS, PCSC, and RANI Headlines

Recent News About These Companies

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

3 hours ago | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

Rani Therapeutics (RANI) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Insider Selling: Rani Therapeutics (NASDAQ:RANI) CEO Sells 8,014 Shares

July 28, 2026 | marketbeat.com

Insider Buying: Rani Therapeutics (NASDAQ:RANI) Director Buys $24,840.00 in Stock

July 28, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Buys 35,000 Shares

July 28, 2026 | marketbeat.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics

July 10, 2026 | yicaiglobal.comY

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

July 9, 2026 | globenewswire.com

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

June 29, 2026 | globenewswire.com

Rani Therapeutics Shareholders Back Board and Auditor at Meeting

May 29, 2026 | tipranks.com

Rani Therapeutics Announces $20 Million Equity Financing

May 27, 2026 | tipranks.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 26, 2026 | globenewswire.com

Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice

May 17, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDNAF, KLRS, PCSC, and RANI Company Descriptions

Kalaris Therapeutics NASDAQ:KLRS

$3.95 -0.12 (-2.97%)

As of 01:56 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Medicenna Therapeutics OTCMKTS:MDNAF

$0.27 0.00 (0.00%)

As of 08/7/2026 03:27 PM Eastern

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Perceptive Capital Solutions NASDAQ:PCSC

$11.95 0.00 (0.00%)

As of 07/21/2026

Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.

Rani Therapeutics NASDAQ:RANI

$0.77 -0.03 (-3.16%)

As of 01:58 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDNAF, KLRS, PCSC, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDNAF, KLRS, PCSC, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDNAF, KLRS, PCSC, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDNAF, KLRS, PCSC, and RANI Company Descriptions

Kalaris Therapeutics NASDAQ:KLRS

Medicenna Therapeutics OTCMKTS:MDNAF

Perceptive Capital Solutions NASDAQ:PCSC

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDNAF, KLRS, PCSC, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDNAF, KLRS, PCSC, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDNAF, KLRS, PCSC, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDNAF, KLRS, PCSC, and RANI Company Descriptions

Kalaris Therapeutics NASDAQ:KLRS

Medicenna Therapeutics OTCMKTS:MDNAF

Perceptive Capital Solutions NASDAQ:PCSC

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools